Navigation Links
ES Vascular Receives CE Mark for its First Aortic Stapler for End-to-End Anastomosis Between Synthetic Grafts and Aorta During Open Repair of Aortic Aneurysmal and Occlusive Disease
Date:4/14/2008

HAIFA, Israel, April 14 /PRNewswire/ -- ES Vascular Ltd. announced today that it has received a CE Mark approval for its Open Aortic Stapler (OAS) system for mechanical suturing technology of aortic synthetic grafts during open repair of AAA and other aortic reconstructions, enabling commercialization of the device in most European countries. Based on its proprietary stapling technology, the OAS stapler is a unique device that enables one shot stapling of synthetic grafts to aorta in open repair of abdominal and thoracic aneurysmal and occlusive disease, replacing lengthy and cumbersome manual suturing in these major procedures.

"We are very pleased to have received CE Mark for our OAS device and will immediately implement our strategy to make it available in approved countries. Positive clinical data position OAS to be a break-through product for patients and physicians alike," said Shuki Porath, CEO of ES Vascular.

Prof. Ralf Kolvenbach, Chief of Vascular Surgery and Endovascular Therapy at Augusta Hospital in Dusseldorf, Germany and a principal investigator for the OAS clinical trial program, commented, "OAS provides the construction of a geometrically perfect, uniform and standardized anastomosis that will not depend on the skills of the surgeon, is one of the principles lying behind the design of the OAS. This safety and feasibility trial showed that we now have the technology to use aortic stapling in a clinical setting. The aortic stapler can create a uniform staple line between any synthetic vascular prosthesis and the aortic wall. It is a simple, safe, rapid and reliable technique to perform a sutureless, end-to-end anastomosis in patients with aortic aneurysms or occlusive disease."

ES Vascular will be presenting the OAS and other products at the MedtechInsight conference "Investment In Innovation (In3) Europe", Paris, April 29-30.

About OAS System

The OAS system is comprised of applier and implantable staples and
'/>"/>

SOURCE ES Vascular Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
2. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
3. Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program
4. First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies OmniWave(TM) Endovascular System
5. LeMaitre Vascular to Participate in 28th Annual Cowen and Company Health Care Conference
6. BioVascular, Inc. Expands Executive Team
7. HealthAware Introduces Its VascularAware Cardiovascular Disease Module
8. Topspin Medical Announces First Commercial Installation of the Cathamaran(TM) Intravascular MRI System
9. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
10. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
11. The Wisconsin Heart Hospital Announces Live Webcast Demonstrating Breakthrough Device to Facilitate Beating Heart and Robotic Coronary Revascularization Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- Decision Resources, one of the world,s leading ... issues, finds that, owing to the launches of ... will increase more than sevenfold from $790 million ... the United States, France, Germany, Italy, Spain, the ... report entitled Atrial Fibrillation finds that ...
(Date:12/14/2009)... - Results From a Survey Conducted by UCB Assessing ... Countries , , - A third of ... impacts their enjoyment of the festive season, ... shopping for gifts, preparing holiday ... difficult to do, - Nearly ...
(Date:12/11/2009)... Dendreon Corporation (Nasdaq: DNDN ) announced today ... offering have exercised in full their option to ... at the public offering price of $24.75 per ... the size of the offering to an aggregate ... expects to receive net proceeds from the offering ...
(Date:12/11/2009)... new explanation for differences in the severity of mental illness ... the more serious the handicap. The genetic defect is situated ... the amount of copies of the GDI1 gene that is ... Journal of Human Genetics , and are the result of ... a life sciences research institute in Flanders, Belgium at the ...
Breaking Biology Technology:The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Amount of gene surplus determines severity of mental retardation in males 2
... Position -, HOPKINTON, Mass., Oct. 29 Caliper ... of tools and services for,drug discovery and life sciences ... sell its Pharmaceutical Development & Quality,Analysis (PDQ) product line ... million. The PDQ product line consists of products used,for ...
... Myers, Inc.,(NYSE: RBN ) announced today that its ... Board of Directors, increasing the size from,seven to eight ... for election at the January 7, 2009 annual shareholder ... board., Richard J. Giromini, 55, is President and ...
... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) today announced ... the company at two upcoming industry and/or investor,conferences:, ... Conference at the,New York Palace Hotel, 455 Madison Ave. ... senior vice president, is scheduled to present,at 9:55 a.m. ...
Other Biology Technology:Caliper Enters Agreement to Divest Non-Core Pharmaceutical Development & Quality Analysis Product Line 2Caliper Enters Agreement to Divest Non-Core Pharmaceutical Development & Quality Analysis Product Line 3Robbins & Myers, Inc. Elects New Board Members 2Trubion Announces Presentations at Upcoming Investor Conferences 2
(Date:12/11/2009)... stress collectively weigh and initiate different survival strategies say ... strategic decisions that affect their health, wealth and the ... this week in the early online edition of the ... , was accomplished when the scientists applied the mathematical ... of genes and proteins that colonies of bacteria rely ...
(Date:12/11/2009)... discoveries about the deep ocean,s temperature variability and circulation ... , The deep ocean is affected more by surface ... more accurate predictions of factors such as sea level ... temperatures have also been found to result in a ... in a faster transport of large quantities of warm ...
(Date:12/11/2009)... is a health risk but why do teens become ... evaluation for Faculty of 1000 Biology, Neil Grunberg looks ... , Grunberg describes the study, published by Natividad et ... suggests it "may have implications to help understand why ... increases the level of dopamine in the brain, a ...
Breaking Biology News(10 mins):Bacteria provide new insights into human decision making 2Bacteria provide new insights into human decision making 3Bacteria provide new insights into human decision making 4Bacteria provide new insights into human decision making 5New discoveries could improve climate projections 2Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 1Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 2Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 3Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 4Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 5Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results 6197 6Leukemia Drug May Help Some Ovarian Cancer Patients 61215 1Leukemia Drug May Help Some Ovarian Cancer Patients 61215 2Service Outsourcing Opportunities in Medical Device Market worth US 2426 77 Billion by 2014 6193 1Service Outsourcing Opportunities in Medical Device Market worth US 2426 77 Billion by 2014 6193 2Service Outsourcing Opportunities in Medical Device Market worth US 2426 77 Billion by 2014 6193 3
... 2008 -- From the collapse of star-forming clouds to the ... gasoline in your car engine to the coursing blood in ... of microscopic animals in the ocean, many of nature,s most ... 61st Annual Meeting of the American Physical Society,s Division of ...
... Ever since the ancient thinker Archimedes shouted "Eureka" in ... out, scientist though the ages have solved many of ... field of fluid dynamics addresses some of the most ... medicine. Later this month, the largest scientific meeting of ...
... HOUSTON -- (Nov. 19, 2008) -- Rice University scientists on ... stubborn pollutant TCE have created a method that lets them ... as individual chemical bonds are formed and broken. , "We ... of our molecules," said researcher Michael Wong. "By watching the ...
Other Biology News:The physics of star-forming clouds and the urban environment 2The physics of star-forming clouds and the urban environment 3The physics of star-forming clouds and the urban environment 4The physics of star-forming clouds and the urban environment 5The physics of star-forming clouds and the urban environment 6Jupiter's shrinking red spot 2Jupiter's shrinking red spot 3Jupiter's shrinking red spot 4Jupiter's shrinking red spot 5Jupiter's shrinking red spot 6Jupiter's shrinking red spot 7Jupiter's shrinking red spot 8Jupiter's shrinking red spot 9Jupiter's shrinking red spot 10Researchers shed new light on catalyzed reactions 2Researchers shed new light on catalyzed reactions 3
ID clarifier: With ethidium bromide (50 μg/ml)...
... C2C12 cells were cultured in DMEM and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
... for optimal colony growth; ... growth of anchorage-dependent cells. ... colony-forming assays of human ... Not suitable for long-term ...
... is a convenient, premixed, formamide-containing ... and Perfect RNA Markers. This ... dilution and is suitable for ... mix equal volumes of RNA ...
Biology Products: